Close Menu

NEW YORK – Agilent Technologies said on Monday that it has priced an underwritten, registered public offering of a series of its senior notes, in an aggregate principal amount of $500 million.

In a filing with the US Securities and Exchange Commission, the company said that the notes will mature in June 2030 and will bear interest at an annual rate of 2.1 percent. The offering is expected to close on June 4, and Agilent is expecting net proceeds of about $494.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.